Skip to main content

ICLR

Stock
Health Care
Diagnostics & Research

Performance overview

ICLR Price
Price Chart

Forward-looking statistics

Beta
0.77
Risk
37.16%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees36K
Market cap$26.4B

Fundamentals

Enterprise value$14.6B
Revenue$8.2B
Revenue per employee—
Profit margin9.25%
Debt to equity37.84

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$9.19
Dividend per share—
Revenue per share$99.94
Avg trading volume (30 day)$175M
Avg trading volume (10 day)$178M
Put-call ratio—

Macro factor sensitivity

Growth+0.2
Credit+2.8
Liquidity-0.2
Inflation-2.7
Commodities+0.8
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio9.96
Price to sales1.46
P/E Ratio9.96
Enterprise Value to Revenue1.78
Price to book1.26

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Here's Why You Should Retain ICLR Stock in Your Portfolio Now

Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.

Zacks Investment Research (June 2, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free